Myogen to Present at the Leerink Swann Vascular Modlulation Conference

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company
focused on the discovery, development and commercialization of small
molecule therapeutics for the treatment of cardiovascular disorders,
today announced that J. William Freytag, President and CEO, will
participate in the Leerink Swann Vascular Modulation Conference to be
held April 28, 2006, in Boston, Massachusetts.
   The Company's presentation will take place at 3:00 p.m. (Eastern)
on Friday, April 28, 2006. There will be a live webcast of the
presentation, which will be accessible through a link posted on the
investor relations section of the Myogen website at
http://investor.myogen.com/. The webcast will be available for replay
on Myogen's website through May 17, 2006.
   Myogen currently has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension and darusentan for the treatment of patients
with resistant hypertension. Myogen and GlaxoSmithKline have entered
into a global PAH partnership in which Myogen has distribution and
marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in
the United States for the treatment of PAH and GlaxoSmithKline has
licensed ambrisentan from Myogen for all territories outside of the
United States. Myogen also conducts a target and drug discovery
research program focused on the development of disease-modifying drugs
for the treatment of chronic heart failure and related cardiovascular
disorders. Please visit Myogen's website at www.myogen.com.

   Safe Harbor Statement

   The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties, including
those to be discussed in the presentation and others that can be found
in the "Risk Factors" section of Myogen's Form 10-K for the year ended
December 31, 2005, and Myogen's periodic reports on Form 10-Q and Form
8-K. Myogen does not undertake any obligation to update any
forward-looking statements contained in the anticipated presentation
as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those projected.